• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    4/19/24 4:31:47 PM ET
    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion.
    • Galera Therapeutics (NASDAQ:GRTX) stock increased by 9.13% to $0.2. The market value of their outstanding shares is at $10.9 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares increased by 8.54% to $0.26. The company's market cap stands at $3.4 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock moved upwards by 6.7% to $0.34.
    • Calidi Biotherapeutics (AMEX:CLDI) shares increased by 6.17% to $0.17. The market value of their outstanding shares is at $8.4 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares increased by 6.04% to $1.04. The company's market cap stands at $264.6 million.

    Losers

    • Vaxxinity (NASDAQ:VAXX) shares decreased by 10.7% to $0.43 during Friday's after-market session. The company's market cap stands at $53.8 million.
    • Titan Pharma (NASDAQ:TTNP) stock declined by 9.26% to $6.37. The market value of their outstanding shares is at $5.8 million.
    • Tiziana Life Sciences (NASDAQ:TLSA) shares decreased by 8.24% to $0.61. The company's market cap stands at $61.4 million.
    • Soligenix (NASDAQ:SNGX) shares decreased by 7.17% to $0.4. The market value of their outstanding shares is at $4.2 million.
    • Clene (NASDAQ:CLNN) stock decreased by 6.94% to $0.33. The company's market cap stands at $41.7 million.
    • Metagenomi (NASDAQ:MGX) stock fell 5.67% to $6.5. The market value of their outstanding shares is at $243.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $CLDI
    $CLNN
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Adaptimmune Therapeutics plc
    $ADAP
    7/29/2025Buy → Neutral
    H.C. Wainwright
    Adaptimmune Therapeutics plc
    $ADAP
    6/26/2025$0.50Outperform → Neutral
    Mizuho
    Adaptimmune Therapeutics plc
    $ADAP
    7/30/2024$4.00Buy
    H.C. Wainwright
    Adaptimmune Therapeutics plc
    $ADAP
    5/30/2024$3.15Sector Outperform
    Scotiabank
    Metagenomi Therapeutics Inc.
    $MGX
    5/7/2024$10.00Buy
    H.C. Wainwright
    Metagenomi Therapeutics Inc.
    $MGX
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    Metagenomi Therapeutics Inc.
    $MGX
    3/5/2024Outperform
    TD Cowen
    Metagenomi Therapeutics Inc.
    $MGX
    3/5/2024$22.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adaptimmune Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adaptimmune Therapeutics from Buy to Neutral

    7/29/25 7:36:15 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptimmune Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Adaptimmune Therapeutics from Outperform to Neutral and set a new price target of $0.50

    6/26/25 7:50:31 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

    7/30/24 6:31:41 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

    AUSTIN, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializ

    3/19/26 8:00:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

    PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that a summary of all the clinical trials completed to date evaluating HyBryte™ (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL) has been published in the peer-reviewed medical journal Expert Opinion on Investigational Drugs. The publication "Topical Hypericin: A Promising Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma" is authored by Brian Poligone, MD, PhD, the founder and Medical

    3/19/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

    In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026Oversubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDACompletion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027 SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Cl

    3/12/26 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    SEC Filings

    View All

    SEC Form 10-K filed by Galera Therapeutics Inc.

    10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    3/19/26 7:15:26 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Clene Inc.

    10-K - Clene Inc. (0001822791) (Filer)

    3/17/26 7:00:40 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Clene Inc.

    8-K - Clene Inc. (0001822791) (Filer)

    3/12/26 8:05:22 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cerrone Gabriele M

    3 - Tiziana Life Sciences Ltd (0001723069) (Issuer)

    3/18/26 9:18:18 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)

    4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)

    3/9/26 5:16:44 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)

    4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)

    3/9/26 5:16:17 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

    New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions expected in 4Q 2026 Organizational restructuring reduced workforce by 25%; Capital allocation strategy anticipated to extend cash runway into the 4Q 2027 Jian Irish, Ph.D., M.B.A., currently President and Chief Operating Officer, appointed as Chief Executive Officer; Brian Thomas, Ph.D., former Chief Executive Officer, continuing on Board of Directors and Dr. Willard Dere serving as new

    11/11/25 4:02:00 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

    Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F

    9/23/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADAP
    $CLDI
    $CLNN
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care